...
首页> 外文期刊>Neurochemistry International: The International Journal for the Rapid Publication of Critical Reviews, Preliminary and Original Research Communications in Neurochemistry >Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson's disease
【24h】

Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson's disease

机译:选择性Magl和FAAH抑制对帕金森病慢性MPTP小鼠模型中多巴胺耗竭和GDNF表达的对比作用

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract The modulation of the brain endocannabinoid system has been identified as an option to treat neurodegenerative diseases including Parkinson's disease (PD). Especially the elevation of endocannabinoid levels by inhibition of hydrolytic degradation represents a valuable approach. To evaluate whether monoacylglycerol lipase (MAGL) or fatty acid amide hydrolase (FAAH) inhibition could be beneficial for PD, we examined in parallel the therapeutic potential of the highly selective MAGL inhibitor KML29 elevating 2-arachidonoylglyerol (2-AG) levels and the highly selective FAAH inhibitor PF-3845 elevating anandamide (AEA) levels in a chronic methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid (MPTP/probenecid) mouse model of PD. Chronic administration of KML29 (10?mg/kg) but not PF-3845 (10?mg/kg) attenuated striatal MPTP/probenecid-induced dopamine depletion. Furthermore, KML29 induced an increase in Gdnf but not Bdnf expression, whereas PF-3845 decreased the MPTP/probenecid-induced Cnr2 expression without any effects on neurotrophin expression. Investigation of treatment-na?ve striatal mRNA levels revealed a high presence of Gdnf and Mgll in contrast to Bdnf and Faah . Treatment of primary mouse microglia with 2-AG increased Gdnf but not Bdnf expression, suggesting that microglia might mediate the observed KML29-induced increase in Gdnf . In summary, pharmacological MAGL but not FAAH inhibition in the chronic MPTP/probenecid model attenuated the MPTP/probenecid-induced effects on striatal dopamine levels which were accompanied by an increase in 2-AG levels. Highlights ? MAGL but not FAAH inhibition attenuates dopamine depletion in a chronic MPTP model. ? MAGL but not FAAH inhibition further increases GDNF expression in chronic MPTP mice. ? 2-AG treatment of primary microglia increases GDNF expression. ? CB2 expression is decreased upon FAAH inhibition in chronic MPTP mice.
机译:摘要脑内瘤素体系的调节已被鉴定为治疗神经变性疾病,包括帕金森病(PD)的选项。特别是通过抑制水解降解的内胆碱水平的升高代表了有价值的方法。为了评估单酰基甘油脂肪酶(Mag1)或脂肪酸酰胺水解酶(FAAH)抑制是否有益于PD,我们并行检查高选择性Mag1抑制剂KML29的治疗潜力,升高2-arachidonylgyerol(2-Ag)水平和高度选择性FAAH抑制剂PF-3845在慢性甲基-4-苯基-1,2,3,6-四氢吡啶/丙烯酸(MPTP / probenecid)小鼠模型中升高Aandamide(AEA)水平Pd的小鼠模型。慢性施用KM129(10?Mg / kg),但不是PF-3845(10?Mg / kg)减毒纹状体MPTP /丙烯酸诱导的多巴胺耗尽。此外,KM129诱导GDNF但不是BDNF表达的增加,而PF-3845降低了MPTP /探针诱导的CNR2表达,而不对神经营养素表达的任何效果。对治疗的调查 - ve纹纹纹纹状体mRNA水平揭示了与BDNF和FAAH相比的GDNF和MGLL的高存在。用2-Ag的初级小鼠小鼠治疗GDNF增加但不是BDNF表达,表明小胶质细胞可能介导观察到的KML29诱导的GDNF增加。总之,药理学魔术师但不是FAAH抑制在慢性MPTP / probenecid模型中,减弱了MPTP /丙种诱导的对纹状体多巴胺水平的影响,伴随着2-AG水平的增加。强调 ? Magl但不是FAAH抑制在慢性MPTP模型中衰减多巴胺枯萎病。还MAGL但不是FAAH抑制进一步增加了慢性MPTP小鼠中的GDNF表达。还2-AG治疗初级小胶质细胞增加GDNF表达。还在慢性MPTP小鼠中对FAAH抑制的表达降低了CB2表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号